Clinical development of phosphatidylinositol-3 kinase pathway inhibitors.
作者： Carlos L. Arteaga
DOI: 10.1007/82_2010_54
关键词: Cancer 、 Phosphatidylinositol 、 Kinase 、 Signal transduction 、 Cancer research 、 Biomarker (cell) 、 Immunology 、 PI3K/AKT/mTOR pathway 、 Clinical trial 、 Enzyme inhibitor 、 Medicine
摘要: The PI3K pathway is the most commonly altered in human cancer. Several recent phase I studies with therapeutic inhibitors of this have shown that pharmacological inhibition humans feasible and overall well tolerated. Furthermore, there has already been clinical evidence anti-tumor activity patients advanced intensity duration required for an antitumor effect optimal pharmacodynamic biomarker(s) inactivation remain to be established. Preclinical early data support focusing on trials are at a minimum enriched alterations signaling pathway. These likely more effective combination established other novel molecular therapies.
springer.com
elsevier.com
sci-hub.se 参考文章(92)
G. Shapiro, E. Kwak, J. Baselga, J. Rodon, C. Scheffold, A. D. Laird, C. Bedell, G. Edelman, Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors Journal of Clinical Oncology. ,vol. 27, pp. 3500- 3500 ,(2009) , 10.1200/JCO.2009.27.15_SUPPL.3500
Horgan K, Salter J, Hills M, Dixon Jm, Harvey E, Dowsett M, Antiproliferative effects of idoxifene in a placebo-controlled trial in primary human breast cancer. Clinical Cancer Research. ,vol. 6, pp. 2260- 2267 ,(2000)
Steven Seelig, Carlos L. Arteaga, Walter King, F. Michael Yakes, Wichai Chinratanalab, Christoph A. Ritter, Herceptin-induced Inhibition of Phosphatidylinositol-3 Kinase and Akt Is Required for Antibody-mediated Effects on p27, Cyclin D1, and Antitumor Action Cancer Research. ,vol. 62, pp. 4132- 4141 ,(2002)
Roger W. Blamey, Mitchell Dowsett, Michael Baum, Nigel J. Bundred, Alan E. Wakeling, Christobel Saunders, Anthony Howell, Robert I. Nicholson, Elizabeth Anderson, John F. Robertson, Robert E. Mansel, Frances Sutcliffe, David J. DeFriend, Peter Walton, Investigation of a New Pure Antiestrogen (ICI 182780) in Women with Primary Breast Cancer Cancer Research. ,vol. 54, pp. 408- 414 ,(1994)
David Solit, Mark M. Moasser, Qing-Bai She, Andrea Basso, Resistance to Gefitinib in PTEN-Null HER-Overexpressing Tumor Cells Can Be Overcome through Restoration of PTEN Function or Pharmacologic Modulation of Constitutive Phosphatidylinositol 3′-Kinase/Akt Pathway Signaling Clinical Cancer Research. ,vol. 9, pp. 4340- 4346 ,(2003)
Teemu T. Junttila, Robert W. Akita, Kathryn Parsons, Carter Fields, Gail D. Lewis Phillips, Lori S. Friedman, Deepak Sampath, Mark X. Sliwkowski, Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941 Cancer Cell. ,vol. 15, pp. 429- 440 ,(2009) , 10.1016/J.CCR.2009.03.020
B Karakas, K E Bachman, B H Park, Mutation of the PIK3CA oncogene in human cancers. British Journal of Cancer. ,vol. 94, pp. 455- 459 ,(2006) , 10.1038/SJ.BJC.6602970
Mariona Graupera, Julie Guillermet-Guibert, Lazaros C Foukas, Li-Kun Phng, Robert J Cain, Ashreena Salpekar, Wayne Pearce, Stephen Meek, Jaime Millan, Pedro R Cutillas, Andrew JH Smith, Anne J Ridley, Christiana Ruhrberg, Holger Gerhardt, Bart Vanhaesebroeck, None, Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration Nature. ,vol. 453, pp. 662- 666 ,(2008) , 10.1038/NATURE06892
Bart Vanhaesebroeck, Sally J. Leevers, George Panayotou, Michael D. Waterfield, Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends in Biochemical Sciences. ,vol. 22, pp. 267- 272 ,(1997) , 10.1016/S0968-0004(97)01061-X
Roberto Bianco, Incheol Shin, Christoph A Ritter, F Michael Yakes, Andrea Basso, Neal Rosen, Junji Tsurutani, Phillip A Dennis, Gordon B Mills, Carlos L Arteaga, Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors Oncogene. ,vol. 22, pp. 2812- 2822 ,(2003) , 10.1038/SJ.ONC.1206388